Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Aspira Womens Health's Enterprise Value is €34.25 Mil.
Aspira Womens Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-17.03 Mil. Therefore, Aspira Womens Health's EV-to-EBIT ratio for today is -2.01.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Aspira Womens Health's Enterprise Value is €34.25 Mil.
Aspira Womens Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-16.84 Mil. Therefore, Aspira Womens Health's EV-to-EBITDA ratio for today is -2.03.
Aspira Womens Health Enterprise Value Historical Data
The historical data trend for Aspira Womens Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aspira Womens Health's Enterprise Value
For the Diagnostics & Research subindustry, Aspira Womens Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Enterprise Value falls into.
Aspira Womens Health Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Aspira Womens Health's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (FRA:CUL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Aspira Womens Health's current Enterprise Value is €34.25 Mil.
Aspira Womens Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.03 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Aspira Womens Health's current Enterprise Value is €34.25 Mil.
Aspira Womens Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.84 Mil.
Aspira Womens Health's current Enterprise Value is €34.25 Mil.
Aspira Womens Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health Enterprise Value Related Terms
Thank you for viewing the detailed overview of Aspira Womens Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Aspira Womens Health (FRA:CUL) Business Description
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:CUL has been successfully added to your 